Opal Therapeutics, a biotech company enabling acceleration of therapeutic and diagnostic development in women’s gynecological health, announced that it has secured a $1.25 million National Science Foundation (NSF) SBIR Phase II award.
As interest and investment in women’s health therapeutics has rapidly grown in the past few years, the shortage of human-relevant preclinical models has created a critical bottleneck, limiting the ability to evaluate and de-risk promising drug candidates before they enter the clinic. Traditional rodent models fail to replicate human disease biology, creating a severe bottleneck that stalls promising drug candidates from ever reaching clinical trials for gynecological health. This challenge is especially severe for chronic conditions such as endometriosis and uterine fibroids, which affect millions of women worldwide and cause debilitating chronic pelvic pain and infertility.
Opal is directly solving this structural bottleneck with its “uterus in a dish” platform, a patient-derived organoid system that enables scalable drug screening on real human disease tissue in early pre-clinical discovery. By isolating cells from menstrual blood and surgical biopsies, Opal has established a large biobank of organoid and cellular models that capture disease signatures of respective patients. With the NSF funding, Opal will scale its laboratory infrastructure and patient-derived organoid manufacturing to meet growing industry demand. By expanding their imaging and inflammation assays, the company will support larger drug-discovery campaigns with reproducible, human-relevant data. Additionally, Opal will grow its internal datasets to build a predictive “uterine atlas,” pairing patient tissue data with computational analysis for deeper in vitro and in silico insights.
“We are entering a new era in women’s health, with exciting scientific and commercial momentum behind the development of new therapies,” said Morgan Stanton, Ph.D., CEO of Opal Therapeutics. “What’s been missing is a real bridge between big ideas and what actually helps patients. That’s the piece Opal is building. Real human uterine tissue models that let scientists see earlier which drugs are worth betting on and get those to the clinic with more confidence.”
See the full NSF award details here.
About Opal Therapeutics
Opal Therapeutics is a San Francisco-based biotechnology company focused on enabling treatments and diagnostics for chronic disease in women’s reproductive health including endometriosis, fibroids, PMOS, and heavy menstrual bleeding. Through an industry-first use of patient-derived uterine organoids and cells, Opal delivers human-relevant biological and drug-response data that helps overcome the limitations of traditional rodent models. By screening therapeutic candidates early in human uterine tissue, Opal is unlocking the next generation of treatments for women. Learn more at www.opaltherapeutics.com
About the NSF’s Small Business Programs
America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development, helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $9 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit seedfund.nsf.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260806597468/en/
Media gallery
